Target Price | $806.00 |
Price | $596.54 |
Potential | 35.11% |
Number of Estimates | 21 |
21 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $806.00. This is 35.11% higher than the current stock price. The highest price target is $958.00 60.59% , the lowest is $535.00 10.32% . | |
A rating was issued by 28 analysts: 22 Analysts recommend Regeneron Pharmaceuticals to buy, 4 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 35.11% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
22 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $13.4b . This is 5.21% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $14.1b 0.03% , the lowest is $12.6b 10.57% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $13.4b | 5.99% |
2026 | $14.3b | 6.86% |
2027 | $15.8b | 10.56% |
2028 | $16.8b | 6.71% |
2029 | $18.1b | 7.39% |
9 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.3b . This is 2.87% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.3b 18.35% , the lowest is $3.5b 21.91% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 2.37% |
---|---|---|
2025 | $4.3b | 7.07% |
2026 | $5.0b | 16.20% |
2027 | $6.1b | 20.67% |
2028 | $6.4b | 4.73% |
2029 | $7.2b | 13.17% |
2024 | 32.79% | 9.82% |
---|---|---|
2025 | 32.41% | 1.16% |
2026 | 35.25% | 8.76% |
2027 | 38.47% | 9.13% |
2028 | 37.75% | 1.87% |
2029 | 39.78% | 5.38% |
10 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $3.3b . This is 23.28% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.1b 3.00% , the lowest is $2.5b 41.26% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 10.27% |
---|---|---|
2025 | $3.3b | 21.38% |
2026 | $3.6b | 10.75% |
2027 | $4.3b | 17.99% |
2028 | $4.8b | 13.08% |
2029 | $5.3b | 10.97% |
2024 | 29.21% | 1.84% |
---|---|---|
2025 | 24.43% | 16.36% |
2026 | 25.32% | 3.64% |
2027 | 27.02% | 6.71% |
2028 | 28.63% | 5.96% |
2029 | 29.58% | 3.32% |
10 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $30.14 . This is 23.29% lower than earnings per share in the financial year 2024. The highest EPS forecast is $38.11 3.00% , the lowest is $23.08 41.26% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $30.14 | 21.39% |
2026 | $33.38 | 10.75% |
2027 | $39.39 | 18.00% |
2028 | $44.54 | 13.07% |
2029 | $49.43 | 10.98% |
Current | 15.18 | 47.69% |
---|---|---|
2025 | 19.79 | 30.37% |
2026 | 17.87 | 9.70% |
2027 | 15.15 | 15.22% |
2028 | 13.39 | 11.62% |
2029 | 12.07 | 9.86% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 4.40 and an P/S ratio of 4.82 .
This results in the following potential growth metrics and future valuations:
Current | 4.17 | 45.56% |
---|---|---|
2025 | 4.40 | 5.54% |
2026 | 4.12 | 6.42% |
2027 | 3.73 | 9.55% |
2028 | 3.49 | 6.29% |
2029 | 3.25 | 6.88% |
Current | 4.57 | 44.65% |
---|---|---|
2025 | 4.82 | 5.50% |
2026 | 4.51 | 6.42% |
2027 | 4.08 | 9.55% |
2028 | 3.83 | 6.29% |
2029 | 3.56 | 6.88% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Citigroup |
Neutral
➜
Buy
|
Upgrade | May 14 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | May 01 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Apr 30 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 30 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Apr 30 2025 |
Analyst Rating | Date |
---|---|
Upgrade
Citigroup:
Neutral
➜
Buy
|
May 14 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
May 01 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 30 2025 |
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Apr 30 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 30 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Apr 30 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Apr 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.